You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Photoacoustic CT for Preclinical Molecular Imaging

    SBC: OPTOSONICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term objective of this collaborative research project is to commercialize a prototype photoacoustic computed-tomography (PCT) scanner for conducting preclinical molecular imaging. This scanner has been developed by OptoSonics with funding from a Fast Track SBIR grant from the National Cancer Institute (R44-CA-102891) and additional private funding fro ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Novel technologies to remove obscuring blood from fine needle aspiration biopsies

    SBC: AFFINERGY, LLC            Topic: NIGMS

    SUMMARY ABSTRACT Fine needle aspirationFNAcytology is the standard technique for evaluating thyroid nodulesHemorrhaging is common during the procedurehoweverleading to an aspirate that is significantly diluted by bloodSubsequent slide preparations are often suboptimalresulting in nondiagnostic outcomes that necessitate additional testing or diagnostic surgeryIn factquality is so unpredictable that ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Medical Images HTML and Clinical Trial Remote Collaboration

    SBC: HEART IMAGING TECHNOLOGIES, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Medical drugs and devices are regulated by the U S Food and Drug Administration FDA based on data from multicenter clinical trials In U S spending on clinical trials was approximately $ billion Over the past decade the efficiency of clinical trials has been improved by electronic data capture EDC systems whose use has increased from to ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma

    SBC: Annias Immunotherapeutics, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Malignant primary brain tumors represent the most frequent cause of cancer death in children and young adults and account for more deaths than cancer of the kidney or melanoma Glioblastoma GBM is uniformly lethal and current therapy is non specific and produces a median overall survival of andlt months In contrast immunotherapeutic approaches are exq ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Self Assembling High Affinity Peptides for Point of Care Drug-Device Combinations

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Infection surrounding metal implants is a common and sometimes devastating cause of implant failure in a number of fields including oral, craniomaxillofacial (CMF), orthopedic, and cardiovascular surgery. These infections, which arise from the establishment of biofilms on device surfaces, not only necessitate new surgeries but in themselves present a significan ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Commercialization of Human Mesothelial Cells for Research

    SBC: Zen-Bio, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Mesothelial cells have been found to be pivotal in tumor metastasis, peritoneal dialysis, and inflammatory response. These cells are specialized epithelial cells that line the peritoneal, pericardial, and pleural cavities and internal organs presenting a barrier to invading organisms and physical damage. Ovarian tumor attachments occur through cancer cells bind ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease

    SBC: T3D Therapeutics, Inc.            Topic: NIA

    DESCRIPTION provided by applicant The purpose of the proposed project is to conduct a Phase a mechanistic clinical proof of concept study of an investigational drug T D which is being developed for the treatment of cognitive and functional decline in Alzheimerandapos s disease patients T D has successfully completed Phase I studies and with data demonstrating robust entry into the b ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Formulations for Injectable Growth Factors

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Over 6.3 million fractures occur each year in the United States alone (Praemer et al. 1999) and approximately 15% of fractures exhibit delayed or impaired healing. The clinical applications currently used to treat delayed fracture require open surgery to insert an autologous bone graft. If open surgery is confounded by co-morbidity or is deemed otherwise undes ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  9. External, High-Intensity Proton Injector with Ultra-Precise Control for Fast Spot Beam Scanning PBRT

    SBC: T Antaya, LLC            Topic: 102

    DESCRIPTION provided by applicant Proton therapy particle accelerators usually cyclotrons are large and expensive devices and only about of proton therapy treatment candidates have access to proton therapy The research at Antaya Science and Technology aims to reduce the overall cost simplify the operation and increase the availability of proton therapy to all candidate patients The p ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Biguanides to Treat Type 2 Diabetes

    SBC: NOVATARG, INC.            Topic: 200

    DESCRIPTION provided by applicant The present Phase SBIR application builds on the previous Phase SBIR award to identify a markedly improved biguanide to replace metformin in the treatment of T D Over new biguanides were synthesized in the Phase work and analyzed for their ability to produce metformin like activity in cells and animal models but at a much lower effective concentratio ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government